Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026
Filed with HKEX · Stock code 1093 · · 6 pages · English
Summary by 6ix AI
Two of the trials have been selected as Late-breaking Abstracts, highlighting their significance in the field. The announcement emphasizes the Group's commitment to advancing cancer treatment through innovative therapies and clinical research.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - results of phase III clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
- Voluntary announcement - Phase Ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in China
- Voluntary announcement - recombinant herpes zoster vaccine (SYS6052) obtains clinical trial approval in the U.S.
- Voluntary announcement - SYS6077 injection obtains clinical trial approval in China
Later from CSPC Pharmaceutical
- Voluntary announcement - data from Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer presented as a rapid oral presentation at the 2026 annual global meeting of the international gynecologic cancer society (igcs 2026)
- Voluntary announcement - SYS6062 (antibody-drug conjugate) obtains clinical trial approval in China
- Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China
- Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme
- Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical